# US 2012/0258095 A1 · Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0258095 A1
- Document ID: US20120258095A1
- Status: Published application
- Kind: A1
- Application number: 13/441,827
- Filed: 2012-04-06
- Published: 2012-10-11
- Earliest claimed: 2011-04-08
- Assignees: Omeros Corporation; University of Leicester
- Inventors: Gregory A. Demopulos; Thomas Dudler; Hans-Wilhelm Schwaeble
- Web page: https://patentgrep.com/patent/US20120258095A1

## CPC

- C07K 16/40: against enzymes
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/12: Antidiarrhoeals
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/14: for baldness or alopecia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 39/00: General protective or antinoxious agents
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

## Claims

### Claim 1

A method of inhibiting MASP-2-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the MASP-2 inhibitory agent is an anti-MASP-2 antibody or fragment thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition increases the survival of red blood cells in the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject exhibits one or more symptoms selected from the group consisting of (i) below normal levels of hemoglobin, (ii) below normal levels of platelets; (iii) above normal levels of reticulocytes, and (iv) above normal levels of bilirubin.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject has previously undergone, or is currently undergoing, treatment with a terminal complement inhibitor that inhibits cleavage of complement protein C5.

### Claim 7 (depends on 1)

The method of claim 1, wherein the method further comprises administering to the subject a terminal complement inhibitor that inhibits cleavage of complement protein C5.

### Claim 8 (depends on 7)

The method of claim 7, wherein the terminal complement inhibitor is a humanized anti-C5 antibody or antigen-binding fragment thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the terminal complement inhibitor is eculizumab.

### Claim 10 (depends on 2)

The method of claim 2, wherein the antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody and a human antibody.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition is administered subcutaneously, intra-muscularly, intra-arterially, intravenously, or as an inhalant.

### Claim 12 (depends on 11)

The method of claim 11, wherein the composition is administered subcutaneously.

### Claim 13

A method of inhibiting MASP-2-dependent complement activation in a subject suffering from or at risk for developing non-Factor H-dependent atypical hemolytic uremic syndrome (aHUS), comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dependent complement activation.

### Claim 14 (depends on 13)

The method of claim 13, wherein prior to administration of the composition the subject is determined to exhibit one or more symptoms selected from the group consisting of (i) anemia, (ii) thrombocytopenia (iii) renal insufficiency and (iv) rising creatinine, and the composition is administered in an effective amount and for a sufficient time period to improve said one or more symptoms.

### Claim 15 (depends on 13)

The method of claim 13, wherein the subject is suffering from aHUS associated with factor I, factor B, or membrane cofactor CD46.

### Claim 16 (depends on 13)

The method of claim 13, wherein the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof.

### Claim 17 (depends on 13)

The method of claim 13, wherein the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6.

### Claim 18

A method for reducing the likelihood that a subject at risk for developing atypical hemolytic uremic syndrome (aHUS) will suffer clinical symptoms associated with aHUS comprising:
(a) determining the presence of a genetic marker in the subject known to be associated with aHUS;
(b) periodically monitoring the subject to determine the presence or absence of at least one symptom selected from the group consisting of anemia, thrombocytopenia, renal insufficiency and rising creatinine; and
(c) administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation upon the determination of the presence of at least one of anemia, thrombocytopenia, renal insufficiency or rising creatinine, wherein the composition is administered in an effective amount and for a sufficient time period to improve said one or more symptoms.

### Claim 19 (depends on 18)

The method of claim 18, wherein the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ NO:6.

### Claim 21 (depends on 18)

The method of claim 18, wherein step (a) comprises performing a genetic screening test on a sample obtained from the subject and identifying the presence of at least one genetic marker associated with aHUS in a gene selected from the group consisting of complement factor H(CFH), factor I (CFI), factor B (CFB), membrane cofactor CD46, C3, complement factor H-related protein (CFHR1), anticoagulant protein thrombodulin (THBD), complement factor H-related protein 3 (CFHR3) and complement factor II-related protein 4 (CFHR4).

### Claim 22 (depends on 18)

The method of claim 18, wherein the method further comprises monitoring the subject for the occurrence of an event known to be associated with 2.5 triggering aHUS clinical symptoms and administering to the subject the composition comprising the MASP-2 inhibitory agent prior to, during, or after the occurrence of the triggering event.

### Claim 23 (depends on 22)

The method of claim 22, wherein the event associated with triggering aHUS clinical symptoms is selected from the group consisting of drug exposure, infection, malignancy, injury, organ or tissue transplant and pregnancy.

### Claim 24 (depends on 23)

The method of claim 23, wherein the infection is a bacterial infection.

### Claim 25 (depends on 18)

The method of claim 18, wherein the composition is administered subcutaneously.

### Claim 26

A method of inhibiting MASP-2-dependent complement activation in a subject suffering from, or at risk for developing, atypical hemolytic uremic syndrome (aHUS) secondary to an infection, comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 complement activation.

### Claim 27 (depends on 26)

The method of claim 26, wherein the subject is suffering from, or at risk for developing non-enteric aHUS associated with an S. pneumonia infection.

### Claim 28 (depends on 26)

The method of claim 26, wherein the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof.

### Claim 29 (depends on 28)

The method of claim 28, wherein the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6.

### Claim 30

A method of treating a subject suffering from atypical hemolytic uremic syndrome (aHUS) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dependent complement activation, wherein the administration of the MASP-2 inhibitory agent is administered via an intravenous catheter or other catheter delivery method.

### Claim 31 (depends on 30)

The method of claim 30, further comprising treating the patient with plasmapheresis.

### Claim 32 (depends on 30)

The method of claim 30, wherein the composition comprising the MASP-2 inhibitory agent is administered in the absence of plasmapheresis.

### Claim 33 (depends on 32)

The method of claim 32, wherein the composition comprising the MASP-2 inhibitory agent is administered via a catheter for a first time period, further comprising administering the composition comprising the MASP-2 inhibitory agent for a second time period, wherein the composition is administered subcutaneously during the second time period.

### Claim 34 (depends on 33)

The method of claim 33, further comprising periodically determining the level of at least one complement factor, wherein the determination of a reduced level of the at least one complement factor in comparison to a standard value or a healthy subject is indicative of the need for continued treatment with the composition.

### Claim 35 (depends on 30)

The method of claim 30, wherein the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof.

### Claim 36 (depends on 35)

The method of claim 35, wherein the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6.

### Claim 37

A method for decreasing the likelihood of developing impaired renal function in a subject at risk for developing hemolytic uremic syndrome (HUS) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dependent complement activation.

### Claim 38 (depends on 37)

The method of claim 37, wherein the subject at risk for developing HUS exhibits at least one or more of the symptoms selected from the group consisting of diarrhea, a hematocrit level of less than 30% with smear evidence of intravascular erythrocyte destruction, thrombocytopenia and rising creatinine levels.

### Claim 39 (depends on 37)

The method of claim 37, wherein the subject is infected with an enterogenic E. coli for which the use of antibiotics is contra-indicated.

### Claim 40 (depends on 37)

The method of claim 37, wherein the subject is infected with shigella or salmonella.

### Claim 41 (depends on 39)

The method of claim 39, wherein the composition comprising the MASP-2 inhibitory agent is administered to the subject during a first time period in the absence of an antibiotic.

### Claim 42 (depends on 40)

The method of claim 40, wherein the composition comprising the MASP-2 inhibitory agent is administered to the subject during a first time period in the presence of an antibiotic.

### Claim 43 (depends on 37, 41, 42)

The method of any one of claim 37, 41 or 42, wherein the MASP-2 inhibitory agent is administered to the subject during the first time period via an intravenous catheter or other catheter delivery method.

### Claim 44 (depends on 41, 42, 43)

The method of claim 41, claim 42 or claim 43, further comprising administering the composition comprising the MASP-2 inhibitory agent for a second time period, wherein the composition is administered subcutaneously during the second time period.

### Claim 45 (depends on 44)

The method of claim 44, further comprising periodically determining the level of at least one complement factor, wherein the determination of a reduced level of the at least one complement factor in comparison to a standard value or a healthy subject is indicative of the need for continued treatment with the composition.

### Claim 46 (depends on 37)

The method of claim 37, wherein the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof.

### Claim 47 (depends on 46)

The method of claim 46, wherein the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof, that specifically binds to a portion of SEQ ID NO:6.

### Claim 48

A method of treating a subject suffering from hemolytic uremic syndrome (HUS) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation, wherein the administration of the MASP-2 inhibitory agent is administered to the subject via an intravenous catheter or other catheter delivery method.

### Claim 49 (depends on 48)

The method of claim 48, further comprising treating the patient with plasmapheresis.

### Claim 50 (depends on 48)

The method of claim 48, wherein the composition comprising the MASP-2 inhibitory agent is administered in the absence of plasmapheresis.

### Claim 51 (depends on 48)

The method of claim 48, wherein the composition comprising the MASP-2 inhibitory agent is administered via a catheter for a first time period, further comprising administering the composition comprising the MASP-2 inhibitory agent for a second time period, wherein the composition is administered subcutaneously during the second time period.

### Claim 52 (depends on 51)

The method of claim 51, further comprising periodically determining the level of at least one complement factor, wherein the determination of a reduced level of the at least one complement factor in comparison to a standard value or a healthy subject is indicative of the need for continued treatment with the composition.

### Claim 53 (depends on 48)

The method of claim 48, wherein the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof.

### Claim 54 (depends on 53)

The method of claim 53, wherein the MASP-2 inhibitory agent is an anti MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ NO:6.

### Claim 55

A method of treating a subject suffering from thrombotic thrombocytopenic purpura (TTP), or exhibiting symptoms consistent with a diagnosis of TTP, comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation, wherein the administration of the MASP-2 inhibitory agent is administered to the subject via an intravenous catheter or other catheter delivery method.

### Claim 56 (depends on 55)

The method of claim 55, wherein the subject exhibits at least one or more symptoms selected from the group consisting of central nervous system involvement, thrombocytopenia, severe cardiac involvement, severe pulmonary involvement, gastro-intestinal infarction and gangrene.

### Claim 57 (depends on 55)

The method of claim 55, wherein the subject tests positive for the presence of an inhibitor of ADAMTS13, and the method further comprises administering an immunosuppressant to the subject.

### Claim 58 (depends on 55)

The method of claim 55, wherein the composition comprising the MASP-2 inhibitory agent is administered for a first time period in the absence of plasmapheresis.

### Claim 59 (depends on 55)

The method of claim 55, wherein the subject tests positive for the presence of an inhibitor of ADAMTS-13, and the method further comprises administering ADAMTS-13.

### Claim 60 (depends on 55)

The method of claim 55, further comprising treating the patient with plasmapheresis.

### Claim 61 (depends on 55)

The method of claim 55, wherein the composition comprising the MAST-2 inhibitory agent is administered in the presence of plasmapheresis.

### Claim 62 (depends on 55)

The method of claim 55, wherein the composition comprising the MASP-2 inhibitory agent is administered via a catheter for a first time period, further comprising administering the composition comprising the MASP-2 inhibitory agent for a second time period, wherein the composition is administered subcutaneously during the second time period.

### Claim 63 (depends on 62)

The method of claim 62, further comprising periodically determining the level of at least one complement factor, wherein the determination of a reduced level of the at least one complement factor in comparison to a standard value or a healthy subject is indicative of the need for continued treatment with the composition.

### Claim 64 (depends on 55)

The method of claim 55, wherein the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof.

### Claim 65 (depends on 54)

The method of claim 54, wherein the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6.

### Claim 66

A method of treating a subject suffering from refractory thrombotic thrombocytopenic purpura (TTP) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dependent complement activation.

### Claim 67 (depends on 66)

The method of claim 66, wherein the composition is administered subcutaneously.

### Claim 68 (depends on 66)

The method of claim 66, further comprising periodically determining the level of at least one complement factor, wherein the determination of a reduced level of the at least one complement factor in comparison to a standard value or a healthy subject is indicative of the need for continued treatment with the composition.

### Claim 69 (depends on 66)

The method of claim 66, wherein the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof.

### Claim 70 (depends on 69)

The method of claim 69, wherein the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6.

### Claim 71

A method of inhibiting MASP-2-dependent complement activation in a subject suffering from cryoglobulinemia, comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dependent complement activation.

### Claim 72 (depends on 71)

The method of claim 71, wherein the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof.

### Claim 73 (depends on 72)

The method of claim 72, wherein the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof.

### Claim 74

A method of inhibiting MASP-2-dependent complement activation in a subject suffering from cold agglultinin disease, comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dependent complement activation.

### Claim 75 (depends on 74)

The method of claim 74, wherein the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof.

### Claim 76 (depends on 75)

The method of claim 75, wherein the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof.

### Claim 77

A method of inhibiting MASP-2 dependent complement activation in a subject suffering from glaucoma, comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dependent complement activation.

### Claim 78 (depends on 77)

The method of claim 77, wherein the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof.

### Claim 79 (depends on 78)

The method of claim 78, wherein the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof.

### Claim 80

A method of inhibiting MASP-2 dependent complement activation in a subject at risk for developing, or is suffering from acute radiation syndrome comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dependent complement activation.

### Claim 81 (depends on 80)

The method of claim 80, wherein the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof.

### Claim 82 (depends on 81)

The method of claim 81, wherein the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof.

### Claim 83 (depends on 81)

The method of claim 81, wherein the MASP-2 inhibitory agent is administered prophylactically to the subject prior to radiation exposure.

### Claim 84 (depends on 81)

The method of claim 81, wherein the MASP-2 inhibitory agent is administered to the subject within 24 hours to 48 hours after radiation exposure.

### Claim 85 (depends on 81)

The method of claim 81, wherein the MASP-2 inhibitory agent is administered to the subject after radiation exposure.
